Reported Earlier, Cytokinetics Says New Trial Data Strengthens Case For Aficamten Across Heart Condition Types
Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that additional results from ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive HCM) and MAPLE-HCM
Cytokinetics tested a heart medicine called aficamten on more patients, and the results look promising for helping different types of heart problems. When a company shares good test results like this, it's a sign their medicine might work well—something to watch as they move toward approval.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.